Penumbra, Inc. (PEN)
USD 252.89
(-3.58%)
USD 252.89
(-3.58%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 66.85 Million USD | -59.7% |
| 2022 | 165.91 Million USD | 45.32% |
| 2021 | 114.16 Million USD | 1400.84% |
| 2020 | 7.6 Million USD | -20.08% |
| 2019 | 9.51 Million USD | 114.03% |
| 2018 | -67.85 Million USD | -33.99% |
| 2017 | -50.63 Million USD | -282.57% |
| 2016 | -13.23 Million USD | 32.29% |
| 2015 | -19.54 Million USD | -494.13% |
| 2014 | -3.29 Million USD | -276.03% |
| 2013 | 1.86 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -59.51 Million USD | -815.23% |
| 2024 Q3 | -53.78 Million USD | 9.62% |
| 2024 Q1 | 8.32 Million USD | -87.55% |
| 2023 Q4 | 66.85 Million USD | -47.78% |
| 2023 Q2 | 117.1 Million USD | -15.65% |
| 2023 Q3 | 128.03 Million USD | 9.33% |
| 2023 Q1 | 138.83 Million USD | -16.32% |
| 2023 FY | 66.85 Million USD | -59.7% |
| 2022 Q2 | 161.67 Million USD | 7.2% |
| 2022 FY | 165.91 Million USD | 45.32% |
| 2022 Q3 | 162.67 Million USD | 0.62% |
| 2022 Q4 | 165.91 Million USD | 1.99% |
| 2022 Q1 | 150.82 Million USD | 32.11% |
| 2021 Q2 | 46.68 Million USD | 120.73% |
| 2021 Q1 | 21.15 Million USD | 178.06% |
| 2021 FY | 114.16 Million USD | 1400.84% |
| 2021 Q3 | 107.81 Million USD | 130.92% |
| 2021 Q4 | 114.16 Million USD | 5.9% |
| 2020 Q4 | 7.6 Million USD | 499.11% |
| 2020 Q3 | -1.9 Million USD | 96.64% |
| 2020 FY | 7.6 Million USD | -20.08% |
| 2020 Q2 | -56.79 Million USD | -873.84% |
| 2020 Q1 | 7.33 Million USD | -22.89% |
| 2019 Q1 | -45.84 Million USD | 32.43% |
| 2019 Q4 | 9.51 Million USD | 115.32% |
| 2019 FY | 9.51 Million USD | 114.03% |
| 2019 Q2 | -27.37 Million USD | 40.3% |
| 2019 Q3 | -62.13 Million USD | -127.01% |
| 2018 FY | -67.85 Million USD | -33.99% |
| 2018 Q2 | -59.7 Million USD | -13.07% |
| 2018 Q1 | -52.8 Million USD | -4.28% |
| 2018 Q4 | -67.85 Million USD | -42.12% |
| 2018 Q3 | -47.74 Million USD | 20.04% |
| 2017 FY | -50.63 Million USD | -282.57% |
| 2017 Q1 | -109.38 Million USD | -726.41% |
| 2017 Q2 | -76.57 Million USD | 29.99% |
| 2017 Q3 | -65.62 Million USD | 14.31% |
| 2017 Q4 | -50.63 Million USD | 22.83% |
| 2016 FY | -13.23 Million USD | 32.29% |
| 2016 Q1 | -17.6 Million USD | 9.93% |
| 2016 Q2 | -13.91 Million USD | 20.97% |
| 2016 Q3 | -15.85 Million USD | -13.96% |
| 2016 Q4 | -13.23 Million USD | 16.52% |
| 2015 Q3 | -159.09 Million USD | -332.75% |
| 2015 Q1 | -8.13 Million USD | -147.17% |
| 2015 FY | -19.54 Million USD | -494.13% |
| 2015 Q4 | -19.54 Million USD | 87.71% |
| 2015 Q2 | -36.76 Million USD | -352.09% |
| 2014 Q4 | -3.29 Million USD | 0.0% |
| 2014 FY | -3.29 Million USD | -276.03% |
| 2013 FY | 1.86 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott Laboratories | 8.97 Billion USD | 99.255% |
| Allurion Technologies Inc. | 3.82 Million USD | -1650.183% |
| Artivion, Inc. | 300.4 Million USD | 77.744% |
| Avanos Medical, Inc. | 121.4 Million USD | 44.928% |
| Butterfly Network, Inc. | -109.6 Million USD | 160.996% |
| Butterfly Network, Inc. | -109.6 Million USD | 160.996% |
| Bio-Rad Laboratories, Inc. | 1 Billion USD | 93.327% |
| Boston Scientific Corporation | 8.62 Billion USD | 99.225% |
| CONMED Corporation | 966.95 Million USD | 93.086% |
| Edwards Lifesciences Corporation | -449.1 Million USD | 114.887% |
| Paragon 28, Inc. | 36.39 Million USD | -83.719% |
| Glaukos Corporation | 290.27 Million USD | 76.967% |
| Globus Medical, Inc. | 53.11 Million USD | -25.879% |
| Inspire Medical Systems, Inc. | -160.69 Million USD | 141.606% |
| Integer Holdings Corporation | 1.01 Billion USD | 93.428% |
| Medtronic plc | 24.76 Billion USD | 99.73% |
| Myomo, Inc. | -6.27 Million USD | 1166.299% |
| Nevro Corp. | 117.61 Million USD | 43.154% |
| Owlet, Inc. | -1.34 Million USD | 5085.611% |
| Vicarious Surgical Inc. | -37.99 Million USD | 275.986% |
| Smith & Nephew plc | 2.78 Billion USD | 97.597% |
| Sonendo, Inc. | 26.34 Million USD | -153.804% |
| STERIS plc | 3.17 Billion USD | 97.895% |
| Stryker Corporation | 10.02 Billion USD | 99.333% |
| Vapotherm, Inc. | 102.66 Million USD | 34.88% |
| Zimmer Biomet Holdings, Inc. | 5.57 Billion USD | 98.802% |